Quick Answer
Summit Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2024.
Summit Therapeutics Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2024 | $0.00 | — |
| 2023 | $0.00 | -100.0% |
| 2022 | $705.0K | -61.0% |
| 2021 | $1.81M | +110.3% |
| 2020 | $860.0K | +15.7% |
| 2019 | $743.0K | -98.7% |
| 2019 | $57.09M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | -100.0% | — |
| June 30, 2023 | $0.00 | -100.0% | — |
| March 31, 2023 | $0.00 | -100.0% | -100.0% |
| September 30, 2022 | $220.0K | -83.2% | -6.4% |
| June 30, 2022 | $235.0K | +312.3% | -6.0% |
| March 31, 2022 | $250.0K | +30.2% | -80.9% |
| September 30, 2021 | $1.31M | +623.2% | +2196.5% |
- Over the 2019–2024 period, Summit Therapeutics Inc.’s total revenue has declined by 100.0% (from $57.09 million to $0.00).
- The most recent figure is from Summit Therapeutics Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: